Abstract 897P
Background
The early response to concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) is closely correlated with prognosis. In this study, we aimed to predict early response using a combined model that combines sub-regional radiomics features from multi-sequence MRI with clinically relevant factors.
Methods
A total of 104 patients with LA-NPC were randomly divided into training and validation cohorts at a ratio of 3:1. Radiomic features were extracted from subregions within the tumor area using the K-means clustering method, and feature selection was performed using LASSO regression. Four models were established: classical radiomics model, clinical medol, Intratumor Heterogeneity (ITH) score-based model and a fusion model combining ITH score with clinical factors. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the models, the combined model incorporating ITH score and clinical factors demonstrated the highest predictive performance in the test cohort (AUC = 0.838). Additionally, the models based on ITH score showed superior prognostic value in both the training cohort (AUC = 0.888) and the test cohort (AUC = 0.833).
Conclusions
The combined model that integrates the ITH score with clinical factors exhibited superior performance in predicting early response following concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank Yuandong Cao, Weilin Xu, and Shu Zhou for their valuable comments and discussions. We also express their gratitude to Jinling Yuan and Mengxing Wu for their assistance with data analysis. This work was supported by the Jiangsu Province Doctoral Start-up Foundation for Entrepreneurship and Innovation (Grant No. 2019303073386ER19) and the Clinical Competence Enhancement Project of Jiangsu Provincial People's Hospital (Grant No. JSPH-MC-2021-17).
Legal entity responsible for the study
The First Affiliated Hospital of Nanjing Medical University.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
792P - The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas
Presenter: Alain Zeimet
Session: Poster session 02
793TiP - A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Presenter: Domenica Lorusso
Session: Poster session 02
795TiP - A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
Presenter: Isabelle Ray-Coquard
Session: Poster session 02
796TiP - Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS)
Presenter: Junhwan Kim
Session: Poster session 02
797TiP - Tislelizumab combined with chemotherapy as neoadjuvant treatment for advanced endometrial cancer: A prospective, single-arm, open-label clinical study
Presenter: Zheng Hu
Session: Poster session 02
798TiP - Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial
Presenter: Susana Banerjee
Session: Poster session 02
856P - Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)
Presenter: Luigi Lorini
Session: Poster session 02
857P - Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial
Presenter: Jing Yan
Session: Poster session 02
Resources:
Abstract